Nuo Therapeutics annual gross margin
2010
2011
2012
2013
2014
2015
2017
2018
2022
2023
2024
2025
Nuo Therapeutics's gross margin was 66.94% for fiscal 2025.
View full Nuo Therapeutics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 66.94% | −10.88 pp |
| 2024 | 2024-12-31 | 77.82% | −1.46 pp |
| 2023 | 2023-12-31 | 79.28% | −3.60 pp |
| 2022 | 2022-12-31 | 82.88% | −5.23 pp |
| 2018 | 2018-12-31 | 88.11% | +139.42 pp |
| 2017 | 2017-12-31 | −51.31% | −82.10 pp |
| 2015 | 2015-12-31 | 30.79% | +18.02 pp |
| 2014 | 2014-12-31 | 12.77% | −14.18 pp |
| 2013 | 2013-12-31 | 26.95% | −36.00 pp |
| 2012 | 2012-12-31 | 62.95% | +0.57 pp |
| 2011 | 2011-12-31 | 62.37% | +3.61 pp |
| 2010 | 2010-12-31 | 58.76% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 66.14% | −11.10 pp |
| Q1 2026 | 2026-03-31 | 65.26% | −9.76 pp |
| Q4 2025 | 2025-12-31 | 62.76% | −15.36 pp |
| Q3 2025 | 2025-09-30 | 60.59% | −12.31 pp |
| Q2 2025 | 2025-06-30 | 77.24% | −4.85 pp |
| Q1 2025 | 2025-03-31 | 75.02% | −3.42 pp |
| Q4 2024 | 2024-12-31 | 78.12% | −0.89 pp |
| Q3 2024 | 2024-09-30 | 72.91% | −3.92 pp |
| Q2 2024 | 2024-06-30 | 82.09% | −0.57 pp |
| Q1 2024 | 2024-03-31 | 78.43% | −4.51 pp |
| Q4 2023 | 2023-12-31 | 79.00% | −3.81 pp |
| Q3 2023 | 2023-09-30 | 76.83% | −6.19 pp |
| Q2 2023 | 2023-06-30 | 82.66% | +42.63 pp |
| Q1 2023 | 2023-03-31 | 82.95% | +59.09 pp |
| Q4 2022 | 2022-12-31 | 82.81% | +55.97 pp |
| Q3 2022 | 2022-09-30 | 83.02% | −13.17 pp |
| Q3 2019 | 2019-09-30 | 40.04% | −42.73 pp |
| Q2 2019 | 2019-06-30 | 23.85% | −48.51 pp |
| Q1 2019 | 2019-03-31 | 26.84% | −42.52 pp |
| Q4 2018 | 2018-12-31 | 96.19% | +137.75 pp |
| Q3 2018 | 2018-09-30 | 82.77% | +145.53 pp |
| Q2 2018 | 2018-06-30 | 72.36% | +119.43 pp |
| Q1 2018 | 2018-03-31 | 69.36% | +125.71 pp |
| Q4 2017 | 2017-12-31 | −41.56% | +15.48 pp |
| Q3 2017 | 2017-09-30 | −62.76% | −106.73 pp |
| Q2 2017 | 2017-06-30 | −47.07% | −75.00 pp |
| Q1 2017 | 2017-03-31 | −56.35% | −82.59 pp |
| Q3 2016 | 2016-09-30 | −57.04% | −74.77 pp |
| Q1 2016 | 2016-03-31 | 43.96% | +2.37 pp |
| Q4 2015 | 2015-12-31 | 27.93% | +37.84 pp |
| Q3 2015 | 2015-09-30 | 26.24% | +5.10 pp |
| Q2 2015 | 2015-06-30 | 17.73% | −0.69 pp |
| Q1 2015 | 2015-03-31 | 41.59% | +20.31 pp |
| Q4 2014 | 2014-12-31 | −9.91% | −24.10 pp |
| Q3 2014 | 2014-09-30 | 21.14% | +5.80 pp |
| Q2 2014 | 2014-06-30 | 18.43% | −25.52 pp |
| Q1 2014 | 2014-03-31 | 21.28% | −23.81 pp |
| Q4 2013 | 2013-12-31 | 14.20% | −34.06 pp |
| Q3 2013 | 2013-09-30 | 15.34% | −27.94 pp |
| Q2 2013 | 2013-06-30 | 43.95% | −29.46 pp |
| Q1 2013 | 2013-03-31 | 45.09% | −26.79 pp |
| Q4 2012 | 2012-12-31 | 48.25% | −27.19 pp |
| Q3 2012 | 2012-09-30 | 43.28% | −9.94 pp |
| Q2 2012 | 2012-06-30 | 73.41% | +19.25 pp |
| Q1 2012 | 2012-03-31 | 71.88% | +19.14 pp |
| Q4 2011 | 2011-12-31 | 75.44% | +16.63 pp |
| Q3 2011 | 2011-09-30 | 53.22% | +12.95 pp |
| Q2 2011 | 2011-06-30 | 54.15% | — |
| Q1 2011 | 2011-03-31 | 52.74% | — |
| Q3 2010 | 2010-09-30 | 58.81% | — |
| Q2 2010 | 2010-06-30 | 40.27% | — |
Over the last five reported fiscal years, Nuo Therapeutics's gross margin increased from −51.31% to 66.94%, a change of +118.25 percentage points. The latest reported quarter, Q2 2026, shows 66.14%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuo Therapeutics filings at SEC.gov ↗